These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35902386)

  • 21. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.
    Arnold SV; Inzucchi SE; Tang F; McGuire DK; Mehta SN; Maddox TM; Goyal A; Sperling LS; Einhorn D; Wong ND; Khunti K; Lam CS; Kosiborod M
    Eur J Prev Cardiol; 2017 Oct; 24(15):1637-1645. PubMed ID: 28870145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
    Sharma A; Pagidipati NJ; Califf RM; McGuire DK; Green JB; Demets D; George JT; Gerstein HC; Hobbs T; Holman RR; Lawson FC; Leiter LA; Pfeffer MA; Reusch J; Riesmeyer JS; Roe MT; Rosenberg Y; Temple R; Wiviott S; McMurray J; Granger C
    Circulation; 2020 Mar; 141(10):843-862. PubMed ID: 31992065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus.
    Fullerton B; Siebenhofer A; Jeitler K; Horvath K; Semlitsch T; Berghold A; Gerlach FM
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD013228. PubMed ID: 30556900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
    Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
    Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA
    Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.
    Fullerton B; Jeitler K; Seitz M; Horvath K; Berghold A; Siebenhofer A
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD009122. PubMed ID: 24526393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review and network meta-analysis.
    Tricco AC; Antony J; Soobiah C; Hemmelgarn B; Moher D; Hutton B; Yu CH; Majumdar SR; Straus SE
    Syst Rev; 2013 Jun; 2():47. PubMed ID: 23810103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
    Ipsen EØ; Madsen KS; Chi Y; Pedersen-Bjergaard U; Richter B; Metzendorf MI; Hemmingsen B
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD013516. PubMed ID: 33210751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials.
    Harman NL; James R; Wilding J; Williamson PR;
    Trials; 2017 Dec; 18(1):597. PubMed ID: 29246177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Complementarity between randomised controlled trials and observational registries : the example of cardiovascular prevention with SGLT2 inhibitors].
    Scheen AJ; Ernest P; Jandrain B
    Rev Med Liege; 2017 Dec; 72(12):563-568. PubMed ID: 29271137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.
    Holman RR; Sourij H; Califf RM
    Lancet; 2014 Jun; 383(9933):2008-17. PubMed ID: 24910232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol.
    Lo MC; Lansang MC
    Am J Ther; 2013; 20(6):638-53. PubMed ID: 20838206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current management of diabetes mellitus and future directions in care.
    Chatterjee S; Davies MJ
    Postgrad Med J; 2015 Nov; 91(1081):612-21. PubMed ID: 26453594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.
    Visser J; Snel M; Van Vliet HA
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD003990. PubMed ID: 23543528
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.